Cargando…

Prevalence and localization of nocturnal epileptiform discharges in mild cognitive impairment

Recent evidence shows that identifying and treating epileptiform abnormalities in patients with Alzheimer’s disease could represent a potential avenue to improve clinical outcome. Specifically, animal and human studies have revealed that in the early phase of Alzheimer’s disease, there is an increas...

Descripción completa

Detalles Bibliográficos
Autores principales: Ciliento, Rosario, Gjini, Klevest, Dabbs, Kevin, Hermann, Bruce, Riedner, Brady, Jones, Stephanie, Fatima, Safoora, Johnson, Sterling, Bendlin, Barbara, Lam, Alice D, Boly, Melanie, Struck, Aaron F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10642616/
https://www.ncbi.nlm.nih.gov/pubmed/37965047
http://dx.doi.org/10.1093/braincomms/fcad302
_version_ 1785147001098207232
author Ciliento, Rosario
Gjini, Klevest
Dabbs, Kevin
Hermann, Bruce
Riedner, Brady
Jones, Stephanie
Fatima, Safoora
Johnson, Sterling
Bendlin, Barbara
Lam, Alice D
Boly, Melanie
Struck, Aaron F
author_facet Ciliento, Rosario
Gjini, Klevest
Dabbs, Kevin
Hermann, Bruce
Riedner, Brady
Jones, Stephanie
Fatima, Safoora
Johnson, Sterling
Bendlin, Barbara
Lam, Alice D
Boly, Melanie
Struck, Aaron F
author_sort Ciliento, Rosario
collection PubMed
description Recent evidence shows that identifying and treating epileptiform abnormalities in patients with Alzheimer’s disease could represent a potential avenue to improve clinical outcome. Specifically, animal and human studies have revealed that in the early phase of Alzheimer’s disease, there is an increased risk of seizures. It has also been demonstrated that the administration of anti-seizure medications can slow the functional progression of the disease only in patients with EEG signs of cortical hyperexcitability. In addition, although it is not known at what disease stage hyperexcitability emerges, there remains no consensus regarding the imaging and diagnostic methods best able to detect interictal events to further distinguish different phenotypes of Alzheimer’s disease. In this exploratory work, we studied 13 subjects with amnestic mild cognitive impairment and 20 healthy controls using overnight high-density EEG with 256 channels. All participants also underwent MRI and neuropsychological assessment. Electronic source reconstruction was also used to better select and localize spikes. We found spikes in six of 13 (46%) amnestic mild cognitive impairment compared with two of 20 (10%) healthy control participants (P = 0.035), representing a spike prevalence similar to that detected in previous studies of patients with early-stage Alzheimer’s disease. The interictal events were low-amplitude temporal spikes more prevalent during non-rapid eye movement sleep. No statistically significant differences were found in cognitive performance between amnestic mild cognitive impairment patients with and without spikes, but a trend in immediate and delayed memory was observed. Moreover, no imaging findings of cortical and subcortical atrophy were found between amnestic mild cognitive impairment participants with and without epileptiform spikes. In summary, our exploratory study shows that patients with amnestic mild cognitive impairment reveal EEG signs of hyperexcitability early in the disease course, while no other significant differences in neuropsychological or imaging features were observed among the subgroups. If confirmed with longitudinal data, these exploratory findings could represent one of the first signatures of a preclinical epileptiform phenotype of amnestic mild cognitive impairment and its progression.
format Online
Article
Text
id pubmed-10642616
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-106426162023-11-14 Prevalence and localization of nocturnal epileptiform discharges in mild cognitive impairment Ciliento, Rosario Gjini, Klevest Dabbs, Kevin Hermann, Bruce Riedner, Brady Jones, Stephanie Fatima, Safoora Johnson, Sterling Bendlin, Barbara Lam, Alice D Boly, Melanie Struck, Aaron F Brain Commun Original Article Recent evidence shows that identifying and treating epileptiform abnormalities in patients with Alzheimer’s disease could represent a potential avenue to improve clinical outcome. Specifically, animal and human studies have revealed that in the early phase of Alzheimer’s disease, there is an increased risk of seizures. It has also been demonstrated that the administration of anti-seizure medications can slow the functional progression of the disease only in patients with EEG signs of cortical hyperexcitability. In addition, although it is not known at what disease stage hyperexcitability emerges, there remains no consensus regarding the imaging and diagnostic methods best able to detect interictal events to further distinguish different phenotypes of Alzheimer’s disease. In this exploratory work, we studied 13 subjects with amnestic mild cognitive impairment and 20 healthy controls using overnight high-density EEG with 256 channels. All participants also underwent MRI and neuropsychological assessment. Electronic source reconstruction was also used to better select and localize spikes. We found spikes in six of 13 (46%) amnestic mild cognitive impairment compared with two of 20 (10%) healthy control participants (P = 0.035), representing a spike prevalence similar to that detected in previous studies of patients with early-stage Alzheimer’s disease. The interictal events were low-amplitude temporal spikes more prevalent during non-rapid eye movement sleep. No statistically significant differences were found in cognitive performance between amnestic mild cognitive impairment patients with and without spikes, but a trend in immediate and delayed memory was observed. Moreover, no imaging findings of cortical and subcortical atrophy were found between amnestic mild cognitive impairment participants with and without epileptiform spikes. In summary, our exploratory study shows that patients with amnestic mild cognitive impairment reveal EEG signs of hyperexcitability early in the disease course, while no other significant differences in neuropsychological or imaging features were observed among the subgroups. If confirmed with longitudinal data, these exploratory findings could represent one of the first signatures of a preclinical epileptiform phenotype of amnestic mild cognitive impairment and its progression. Oxford University Press 2023-11-08 /pmc/articles/PMC10642616/ /pubmed/37965047 http://dx.doi.org/10.1093/braincomms/fcad302 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of the Guarantors of Brain. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Ciliento, Rosario
Gjini, Klevest
Dabbs, Kevin
Hermann, Bruce
Riedner, Brady
Jones, Stephanie
Fatima, Safoora
Johnson, Sterling
Bendlin, Barbara
Lam, Alice D
Boly, Melanie
Struck, Aaron F
Prevalence and localization of nocturnal epileptiform discharges in mild cognitive impairment
title Prevalence and localization of nocturnal epileptiform discharges in mild cognitive impairment
title_full Prevalence and localization of nocturnal epileptiform discharges in mild cognitive impairment
title_fullStr Prevalence and localization of nocturnal epileptiform discharges in mild cognitive impairment
title_full_unstemmed Prevalence and localization of nocturnal epileptiform discharges in mild cognitive impairment
title_short Prevalence and localization of nocturnal epileptiform discharges in mild cognitive impairment
title_sort prevalence and localization of nocturnal epileptiform discharges in mild cognitive impairment
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10642616/
https://www.ncbi.nlm.nih.gov/pubmed/37965047
http://dx.doi.org/10.1093/braincomms/fcad302
work_keys_str_mv AT cilientorosario prevalenceandlocalizationofnocturnalepileptiformdischargesinmildcognitiveimpairment
AT gjiniklevest prevalenceandlocalizationofnocturnalepileptiformdischargesinmildcognitiveimpairment
AT dabbskevin prevalenceandlocalizationofnocturnalepileptiformdischargesinmildcognitiveimpairment
AT hermannbruce prevalenceandlocalizationofnocturnalepileptiformdischargesinmildcognitiveimpairment
AT riednerbrady prevalenceandlocalizationofnocturnalepileptiformdischargesinmildcognitiveimpairment
AT jonesstephanie prevalenceandlocalizationofnocturnalepileptiformdischargesinmildcognitiveimpairment
AT fatimasafoora prevalenceandlocalizationofnocturnalepileptiformdischargesinmildcognitiveimpairment
AT johnsonsterling prevalenceandlocalizationofnocturnalepileptiformdischargesinmildcognitiveimpairment
AT bendlinbarbara prevalenceandlocalizationofnocturnalepileptiformdischargesinmildcognitiveimpairment
AT lamaliced prevalenceandlocalizationofnocturnalepileptiformdischargesinmildcognitiveimpairment
AT bolymelanie prevalenceandlocalizationofnocturnalepileptiformdischargesinmildcognitiveimpairment
AT struckaaronf prevalenceandlocalizationofnocturnalepileptiformdischargesinmildcognitiveimpairment